SCHEMBL25303322

SCHEMBL25303322

COC(=O)c1c[nH]c2ccc(C3CC(=O)C3)cc12

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 10/20 0.59
▸ CREBBP Q92793 1/20 0.52
▸ HTR4 Q13639 3/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MITF O75030 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TLR9 Q9NR96 1/20 0.40
▸ TLR8 Q9NR97 1/20 0.40
▸ MAP2K1 Q02750 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ PYGL P06737 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30589687 1.00 NR4A2 (0.59) NR4A2CREBBPHTR4MEN1KMT2A
SCHEMBL25300122 0.93 NR4A2 (0.52) NR4A2CREBBPHTR4MEN1KMT2A
SCHEMBL25300121 0.93 NR4A2 (0.52) NR4A2CREBBPHTR4MEN1KMT2A
SCHEMBL30589684 0.85 NR4A2 (0.59) NR4A2CREBBPHTR4MEN1KMT2A
SCHEMBL25294847 0.85 NR4A2 (0.59) NR4A2CREBBPHTR4MEN1KMT2A
SCHEMBL25294848 0.85 NR4A2 (0.59) NR4A2CREBBPHTR4MEN1KMT2A
SCHEMBL2781955 0.79 NR4A2 (0.52) NR4A2CREBBPKMT2AMAPTALDH1A1
SCHEMBL25978407 0.78 NR4A2 (0.60) NR4A2CREBBPHTR4MEN1KMT2A
SCHEMBL19952517 0.78 NR4A2 (0.48) NR4A2LMNAMAPTTLR9TLR8
SCHEMBL29584817 0.78 NR4A2 (0.48) NR4A2LMNAMAPTTLR9TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463442-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM Due, Inc. (US) 2024-11-20 — — EP disclosed
CN-118613473-A Compounds and compositions for treating disorders associated with STING activity 艾福姆德尤股份有限公司 2024-09-06 — — CN disclosed
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 — — US disclosed
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 — — US disclosed
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 — — US disclosed
WO-2023137034-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2023-07-20 — — WO disclosed
WO-2023137034-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2023-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 NR4A2 2070/4885CREBBP 87/4885HTR4 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback